June 06, 2011
Read more
Trifunctional Antibody Catumaxomab Triggers Vaccination Effect Against Cancer
Read more
Key information on Triomab®
Triomab® backgrounder
Triomab® Mode of Action
The "tri-cell complexes" mediated by Triomab® antibodies simultaneously trigger major immune defense cascades involving the innate as well as the adaptive immune system:
The resulting tri-cell complex triggers several immune defense cascades at the same time:
- T cells, being the most potent killer cells of the human body, induce highly effective tumor cell lysis and apoptosis of tumor cells. In addition, they trigger the typical necrotic processes of tumor cell killing (rounding, swelling, disrupting).
- Accessory cells such as monocytes, macrophages and natural killer cells eliminate tumor cells by, for example, phagocytosis or apoptosis. Moreover, they release cytokines which further stimulate T cell activity.
- Dendritic cells can induce long-lasting immunity against cancer by processing and subsequently presenting tumor cell debris to the immune system.
This unique mode of action makes Triomab® antibodies at least 1,000-fold more effective in destroying cancer cells than conventional monospecific antibodies. Whereas these are applied in doses of milligrams or grams, Triomab® antibodies work in the range of micrograms and can thus be produced in much smaller facilities.